| Joely Ann Heidinger, CRNP | |
|
100 N Bellefield Ave Lowr Level, Pittsburgh, PA 15213-2600 | |
| (412) 579-9338 | |
| Not Available |
| Full Name | Joely Ann Heidinger |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 100 N Bellefield Ave Lowr Level, Pittsburgh, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184241499 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | TP005077B (Pennsylvania) | Primary |
| Entity Name | University Of Pittsburgh Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619935004 PECOS PAC ID: 8729990239 Enrollment ID: O20040308000883 |
News Archive
Major achievements have been made in the domestic HIV/AIDS response as a result of increased realignment and coordination of efforts at the federal level. However, that level of consistent coordination and alignment has yet to take place in most states. In an effort to identify what needs to be done, amfAR, The Foundation for AIDS Research, in collaboration with the National HIV/AIDS Initiative at the O'Neill Institute for National and Global Health Law at Georgetown Law, has released a set of recommendations for how states across the U.S. can improve HIV prevention and care outcomes in an effort to achieve the goals identified within the National HIV/AIDS Strategy.
The federal Centers for Disease Control and Prevention is awarding researchers at the Cook County Health & Hospitals System and Rush University Medical Center a $2 million grant to continue a successful program aimed at preventing healthcare-associated infections, antibiotic resistance, and other adverse events associated with healthcare.
An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.
Grifols, S.A. and Talecris Biotherapeutics Holdings Corp. announced today that the U.S. Federal Trade Commission has accepted for public comment a Consent Agreement that outlines the conditions necessary for Grifols' acquisition of Talecris to proceed.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joely Ann Heidinger, CRNP 100 N Bellefield Ave Lowr Level, Pittsburgh, PA 15213-2600 Ph: (412) 578-9338 | Joely Ann Heidinger, CRNP 100 N Bellefield Ave Lowr Level, Pittsburgh, PA 15213-2600 Ph: (412) 579-9338 |
News Archive
Major achievements have been made in the domestic HIV/AIDS response as a result of increased realignment and coordination of efforts at the federal level. However, that level of consistent coordination and alignment has yet to take place in most states. In an effort to identify what needs to be done, amfAR, The Foundation for AIDS Research, in collaboration with the National HIV/AIDS Initiative at the O'Neill Institute for National and Global Health Law at Georgetown Law, has released a set of recommendations for how states across the U.S. can improve HIV prevention and care outcomes in an effort to achieve the goals identified within the National HIV/AIDS Strategy.
The federal Centers for Disease Control and Prevention is awarding researchers at the Cook County Health & Hospitals System and Rush University Medical Center a $2 million grant to continue a successful program aimed at preventing healthcare-associated infections, antibiotic resistance, and other adverse events associated with healthcare.
An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.
Grifols, S.A. and Talecris Biotherapeutics Holdings Corp. announced today that the U.S. Federal Trade Commission has accepted for public comment a Consent Agreement that outlines the conditions necessary for Grifols' acquisition of Talecris to proceed.
› Verified 7 days ago
Christian Lima, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Delafield Rd, Suite 313, Pittsburgh, PA 15215 Phone: 412-781-0400 | |
Brianne Leigh Wehner, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 Forbes Ave 3rd Floor Gumberg, Pittsburgh, PA 15282 Phone: 412-396-1650 | |
Gorka Murga, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2310 Jane St, Pittsburgh, PA 15203 Phone: 412-586-1755 | |
Bruce Richard Kelly, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 320 Guys Run Road, Pittsburgh, PA 15238 Phone: 412-435-0005 Fax: 412-435-0003 | |
Dr. John Joseph Danek, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 575 Coal Valley Road, Suite 502, Jefferson Regional Medical Center, Pittsburgh, PA 15236 Phone: 412-469-5983 Fax: 412-469-5946 | |
Dr. William E Chelen, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 120 Marion St., Pittsburgh, PA 15219 Phone: 412-232-3555 | |
Valerie Wislo, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7175 Saltsburg Rd, Pittsburgh, PA 15235 Phone: 412-795-7366 |